Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

Also called NCT02334254

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02334254
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02334254. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Intervention (Drug)
rivaroxaban and ticagrel therapy
Intervention (Drug)
triple antithrombotic regimen with warfarin, asipirin and clopidogrel
Lead sponsor
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct02334254
Content hash
5949e2b0ea6f2a4b67c4deee6934fce0cbc4c6c3a2c95df8e8f3d093dc399ffd